Cynapsus Therapeutics Begins Trading on the OTCQX Marketplace in the United States

Cynapsus Therapeutics Inc. (TSX VENTURE:CTH) (OTCQX:CYNAF) ("Cynapsus" or the
"Corporation") today announced that its common shares have been approved for
trading in the United States on the OTCQX marketplace ("OTCQX"). Trading is
expected to commence immediately on OTCQX International under the symbol CYNAF.
The Corporation will continue to trade on the TSX Venture Exchange under its
existing symbol CTH.


OTCQX International is a segment of the OTCQX marketplace reserved for
high-quality non-U.S. companies that are listed on a qualified foreign stock
exchange, undergo management reviews and provide their home country disclosure
to U.S. investors. U.S. investors can find information and Real-Time Level 2
quotes for the Corporation on www.otcmarkets.com. Troutman Sanders LLP will act
as the Corporation's Principal American Liaison ("PAL") on the OTCQX.


Anthony Giovinazzo, Cynapsus' President and Chief Executive Officer said, "We
are very pleased to have achieved this strategic objective of providing U.S.
investors with efficient access to our stock. We believe that all shareholders
will benefit from the Corporation's exposure to a larger number of retail and
institutional investors."


About Cynapsus Therapeutics

Cynapsus is a specialty pharmaceutical company developing the only oral
(sublingual) delivery of the only approved drug (apomorphine) to be used as a
rescue therapy for "off" motor symptoms of Parkinson's disease. Over one million
people in the U.S. and an estimated 5 million people globally suffer from
Parkinson's disease. Parkinson's disease is a chronic and progressive
neurodegenerative disease that impacts motor activity, and its prevalence is
increasing with the aging of the population. Based on a recent study and the
results of the Company's Global 500 Neurologists Survey, it is estimated that
between 25 percent and 50 percent of patients experience "off" episodes in which
they have impaired movement or speaking capabilities. Current medications only
control the disease's symptoms, and most drugs become less effective over time
as the disease progresses.


Cynapsus' drug candidate, APL-130277, is an easy-to-administer, fast-acting
reformulation of apomorphine, which is approved in an injection formulation to
rescue patients from "off" episodes. Cynapsus is focused on maximizing the value
of APL-130277 by completing pivotal studies in advance of a New Drug Application
expected to be submitted in 2015. Cynapsus anticipates a trade sale or
out-licensing to an appropriate global pharmaceutical partner before such an
application is submitted.


More information about Cynapsus (TSX VENTURE:CTH) (OTCQX:CYNAF) is available at
www.cynapsus.ca and at the System for Electronic Document Analysis and Retrieval
(SEDAR) at www.sedar.com.


Forward Looking Statements

This announcement contains "forward-looking statements" within the meaning of
applicable Canadian securities legislation. Generally, these forward-looking
statements can be identified by the use of forward-looking terminology such as
"plans", "expects" or "does not expect", "is expected", "budget", "scheduled",
"estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or
"believes" or variations of such words and phrases or state that certain
actions, events or results "may", "could", "would", "might" or "will be taken",
"occur" or "be achieved". Forward-looking statements are subject to known and
unknown risks, uncertainties and other factors that may cause the actual
results, level of activity, performance or achievements of Cynapsus to be
materially different from those expressed or implied by such forward-looking
statements, including but not limited to those risks and uncertainties relating
to Cynapsus' business disclosed under the heading "Risk Factors" in its Annual
Information Form filed on November 1, 2012 and its other filings with the
various Canadian securities regulators which are available online at
www.sedar.com. Although Cynapsus has attempted to identify important factors
that could cause actual results to differ materially from those contained in
forward-looking statements, there may be other factors that cause results not to
be as anticipated, estimated or intended. There can be no assurance that such
statements will prove to be accurate, as actual results and future events could
differ materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward-looking statements. Cynapsus
does not undertake to update any forward-looking statements, except in
accordance with applicable securities laws.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Cynapsus Therapeutics:
Anthony Giovinazzo
President and CEO
[phone] x225
[e-mail]


Cynapsus Therapeutics:
Andrew Williams
COO & CFO
[phone] x253
[e-mail]
www.cynapsus.ca